Skip to main content

Read the latest news about research on treatments for Alzheimer's disease.

14 Jun | 2021

The United States approves the commercialization of a drug that could slow down Alzheimer's disease

The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.

16 Sep | 2020

The FDA accepts license application for aducanumab, the first possible disease modifying drug for Alzheimer’s

Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.

22 Mar | 2019

Dr. José Luis Molinuevo on the closure of Biogen's clinical trials

The scientific director of BBRC's Alzheimer’s Prevention Program suggests trying a new aproach in order to keep working with Aducanumab

08 Jan | 2019

BBRC launches new study with umbilical cord blood from the Blood and Tissue Bank

The aim of the project, entitled AlfaAge, is to identify pro-ageing and pro-youthful blood biomarkers in different age groups.

29 Jan | 2018

BBRC starts BioAlfa, a novel research on cerebral pro-ageing and pro-youthful blood factors

The project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie action grant agreement No 752310.

30 Oct | 2018

BBRC researchers participate in the 11th Clinical Trials on Alzheimer’s disease

CTAD conference took place in Barcelona, from the 24th to the 27th of October.

19 Apr | 2018

Barcelonaβeta Brain Research Center brings to Spain clinical trials in healthy people to prevent Alzheimer’s disease

The studies will analyze the efficacy of various pharmacological treatments designed to act before the manifestation of the clinical symptoms of the disease.